Meningococcal Vaccines Market Synopsis

Meningococcal Vaccines Market Size Was Valued at USD 3.73 Billion in 2023, and is Projected to Reach USD 8.80 Billion by 2032, Growing at a CAGR of 10.02% From 2024-2032.

Meningococcal vaccines market include the products for managing the vaccine that may protect against diseases caused by Neisseria meningitidis that is a certain bacterium which causes very severe diseases like meningitis or septicemia. Such vaccines are important for population health protection; specifically, for communities that are concerned with meningococcal disease as a continual threat or during potential outbreaks. The market encompasses polysaccharide vaccines, conjugate vaccines, and serogroup B vaccines directed at distinct strains of the bacterium. The drivers for this market include meningococcal diseases, government coverage for immunization, and increasing incidence of outbreaks including among adults and teenagers.

• The market for meningococcal vaccines has emerged in the recent past due to growing knowledge as well as the campaigns on meningococcal diseases in different parts of the world. Meningococcal diseases refer to diseases arising from the Neisseria meningitidis bacterium and include meningitis and septicemia, both of which are life threatening. Thus, the increasing rates of these diseases and their increased severity in infants, adolescents and young people have led to a renewed emphasis on the organization of vaccination. National immunization programs are therefore enforcing aggressive vaccination drives against the infections thus leading to increased use of meningococcal vaccines.
• The market has conjugate vaccines for serogroups A and C, polysaccharide vaccines that target serogroups A and C, and recombinant serogroup B vaccines. Among these, conjugate vaccines have attracted much attention because of their ability to afford long-term protection of the disease as well as prevent the occurrence of the diseases. Market leaders are interested in creating new products and expanding the list of available vaccines; now, GlaxoSmithKline, Pfizer, and Sanofi Pasteur are working on the manufacturers of new forms and types of vaccines. Besides, improvement in terms of equipment technology in vaccine development and higher investment in the public health sector is anticipated to drive market growth.
• According to the geographical analysis, North America and European countries have the highest market share in meningococcal vaccines due to high immunization coverage and good infrastructure. Yet, greater attention is being paid to the Asia-Pacific and Latin American regions, where healthcare costs and information are increasing the demand for vaccines. The recent COVID-19 pandemic has put focus back to preventive medicine hence more funding from the governments and private sector to vaccines. Therefore, there is likelihood of the meningococcal vaccines market to grow steadily throughout the forecast years, with more focus on increasing vaccine vaccinations and immunization rates across the globe.

Meningococcal Vaccines Market Trend Analysis

A Growing Response to Rising Incidence and Public Health Initiatives

• New meningococcal infections are increasingly common, especially among young people between the ages of 15 and 24, as the authorities respond internationally. The above demographics are vulnerable to meningococcal disease, this leads to various illnesses and sometimes death. As a result, health organizations are gradually raising the level of organization of vaccination campaign, paying special attention to the propagation of information regarding the hazards linked with these infections and the efficacy of the vaccine as a sort of protection. This improvement is putting pressure on meningococcal vaccines, particularly conjugate vaccines; which provide coverage for a wide variety of serogroups, including A, C, W and Y. In light of this it is imperative that such vaccines become focal in the bid to decrease the rates of invasive meningococcal disease and obtain herd immunity within communities.
• Meningococcal, single-serogroup vaccines have added a new investment of combination vaccines to the meningococcal vaccines market. These new products provide protection against meningococcal diseases and also provide coverage for other serious diseases including Hib thus making future immunization schedules easier for doctors and their patients. Since several vaccinations are given in one dose, these combined vaccines improve coverage and promote more frequent use of vaccines among children who may otherwise require some of the vaccinations and neglect others. Also, improvements in formulation and delivery systems for the existing vaccines would add value to these vaccines and make these vaccines more appealing to those who have not taken the vaccines. For the meningococcal vaccines market, ongoing developments in public health interventions hold concurrent promises in terms of market growth by broader audience need and innovation in the products offered to the public, which in turn would improve the global health.

The Impact of Technological Advancements and Strategic Partnerships on the Meningococcal Vaccines Market

• Innovation has been greatly influencing the meningococcal vaccines market as research into further improvements of the vaccine is pursued in order to improve its efficacy and safety. This has seen other approaches to formulating vaccines being made by researchers, including the formulation of intranasal vaccines. These methods of delivery are not only beneficial in trying to develop effectiveness of the vaccine but also in coming up with a product that will be more palatable to the patient since it does not involve inject able needles. The convenience of use of intranasal vaccines could be a major plus in mobilizing the youth and other age groups to embrace vaccinations. The follow up with these enhancements increases the tolerability and availability of the meningococcal vaccines making a great impact in the occurrence of meningococcal disease.
• Furthermore, the collaboration between the pharmaceutical industry and governments is getting more crucial in the efforts to increase vaccine coverage, especially in LMICs where the disease burden of meningococcal disease is projected to be the highest. They contribute to reaching and extending the access to vaccines to the target groups making immunization affordable by the needy. The World Health organizations is particularly directing meningococcal vaccination, and acknowledging the use of disparities in health care provision. Thus, the additional growth in market size and higher potential appear to be ensured by such factors as continued improvement in the technology used in vaccines, availability, and development of health care frameworks. Such collaboration is about attaining high level of vaccine coverage among populace and therefore decreasing the incidence of meningococcal disease globally.

Meningococcal Vaccines Market Segment Analysis:

Meningococcal Vaccines Market Segmented based on By Type, By Brand, By Serotype and By Sales Channel.

By Type, Bivalent segment is expected to dominate the market during the forecast period

• For many serotypes of Neisseria meningitidis bivalent vaccines are extremely important preventing them from causing meningococcal disease. Through the presentation of antigens of serotypes A and C or B and C these vaccines increase the immune response of the immune system and thereby increases the ability of the body to detect and fight the pathogens. Such a combined strategy is most effective where outbreaks of meningococcal disease occur – besides protecting individual persons, it contributes to the building of herd immunity in a community. Herd immunity is the situation that exists when an increased population of people is protected against the disease through immunization and this way preventing widespread contraction of the disease in the populace.
• The application of bivalent vaccines is justified primarily during endemic periods when the prevalence of specific serotypes is observed. For example, serotype A has previously been associated with severe cases in some regions of the sub-Saharan area and serotype C in several countries of the world. As a result of offering protection against these particular strains, bivalent vaccines reduce the likelihood of disease, and subsequent complications as neurological impairment or even death. Additionally, broader protective immunity generated by these vaccines also creates better focus on school and community based vaccination campaigns which when implemented makes a tremendous improvement on overall health of the affected population and a consequently lowered burden of meningococcal disease.

By Serotype, Serotype A segment held the largest share in 2023

• Serotype A of Neisseria meningitidis has been particularly aggressive and has been responsible for the majority of meningococcal disease epidemics worldwide and particularly in Sub–Saharan Africa. This region has suffered severe epidemic outbreaks which are marked by high rate of incidence and mortality due to the mobility in the population that rarely has access to medical facilities in spreading of the serotype A. This results in large epidemic patterns because this serotype is favoured by such conditions like overcrowding, movements within selected seasons and low or ineffective vaccination coverage. Subsequently, the physicians of public health have realised the need to control serotype A and the right vaccination measures have to be taken.
• The vaccine, specifically against serotype A has been shown to be important interventions in controlling meningococcal disease. During mass immunization campaigns, mass immunization campaign leaders have recorded colossal drops of incidence rates by the national implementation of the MenAfriVac vaccine, which is a conjugate vaccine primarily designed and developed to target serotype A. Such vaccination campaigns have not only reduced affected cases but also brought considerable positive changes within health risks within at risk populations. Since these vaccines increase immunity against serotype A, they are very useful for controlling the outbreak, decreasing the number of hospitalizations as well as providing lives. Supplementary immunization activities are the best way to keep the communities gains achieved and guarantee that high risk groups are shielded from this potent serotype.

Meningococcal Vaccines Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The meningococcal vaccines consumption market in North America is closely linked to expressed governmental concerns for increasing immunization rates. The U.S. Centers for Disease Control and Prevention (CDC) takes a central part in this and provides clear recommendations on meningococcal vaccination of adolescents/young adults and especially those entering college or living in other group settings. It not only educates the targeted people about the dangers related to meningococcal disease but also ensures practitioners to concentrate on vaccination during normal health check-ups. Thus, to facilitate meningococcal vaccination and to protect student populations, states have instituted school-entry requirements about frequent vaccination. Partnership with school going children and their institutions enhance a sound platform for improvement of immunization rates.
• Further, owing to modern production of immunological preparations, the efficiency of the immunization processes, in North America, has increased significantly due to the existence of more potent and further developed formulations of vaccines. New types of vaccines have been designed to fight not only one but several varieties of the Neisseria meningitidis bacterium, therefore it is much harder for the disease to re-emerge. It has several important contenders that include ‘‘drug developed companies’’ who allocate significant resources in funding novel vaccines. This not only improves vaccine effectiveness, but also increases the level of trust of people in vaccines. The regions have already had a strong framework for health care coverage, which provides access to the healthcare network, efficient distribution of vaccines and timely immunization for the avoidance of meningococcal disease among a population. All these factors give the needed support to promulgate and vigore the meningococcal vaccines market in the North America.

Active Key Players in the Meningococcal Vaccines Market

• Pfizer Inc.
• Sanofi
• Serum Institute of India Ltd.
• GSK plc.
• Merck & co., Inc.
• Walvax Biotechnology Co., Ltd.
• Other Key Players

Key Industry Developments in the Meningococcal Vaccines Market:

• In April 2024, Nigeria made history by introducing the world's first 5-in-1 meningitis vaccine, Men5CV. The vaccine, recommended by WHO, aims to combat the deadly disease, with an initial campaign targeting over one million people aged 1-29.
• In November 2023, GlobalData reported significant changes in the meningococcal vaccine market with the launch of Pfizer's Penbraya. The CDC's Advisory Committee on Immunisation Practices recommended administering Penbraya alongside MenACWY and MenB vaccines for eligible patients aged 10 years and older.
• In July 2023, the Serum Institute of India announced that its multivalent meningococcal meningitis vaccine, designed to combat the five predominant strains in Africa, had received WHO prequalification. This approval made the vaccine eligible for procurement by UN agencies and Gavi, the Vaccine Alliance.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Meningococcal Vaccines Market by Type
 4.1 Meningococcal Vaccines Market Snapshot and Growth Engine
 4.2 Meningococcal Vaccines Market Overview
 4.3 Bivalent
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Bivalent: Geographic Segmentation Analysis
 4.4 Quadrivalent
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Quadrivalent: Geographic Segmentation Analysis
 4.5 Others
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Others: Geographic Segmentation Analysis

Chapter 5: Meningococcal Vaccines Market by Brand
 5.1 Meningococcal Vaccines Market Snapshot and Growth Engine
 5.2 Meningococcal Vaccines Market Overview
 5.3 Menactra
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Menactra: Geographic Segmentation Analysis
 5.4 Menveo
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Menveo: Geographic Segmentation Analysis
 5.5 Nimenrix
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Nimenrix: Geographic Segmentation Analysis
 5.6 Trumenba
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Trumenba: Geographic Segmentation Analysis
 5.7 Bexsero
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Bexsero: Geographic Segmentation Analysis
 5.8 Others
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Others: Geographic Segmentation Analysis

Chapter 6: Meningococcal Vaccines Market by Serotype
 6.1 Meningococcal Vaccines Market Snapshot and Growth Engine
 6.2 Meningococcal Vaccines Market Overview
 6.3 Serotype A
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Serotype A: Geographic Segmentation Analysis
 6.4 Serotype B
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Serotype B: Geographic Segmentation Analysis
 6.5 Serotype C
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Serotype C: Geographic Segmentation Analysis
 6.6 Serotype W-135
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Serotype W-135: Geographic Segmentation Analysis
 6.7 Serotype Y
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Serotype Y: Geographic Segmentation Analysis

Chapter 7: Meningococcal Vaccines Market by Sales Channel
 7.1 Meningococcal Vaccines Market Snapshot and Growth Engine
 7.2 Meningococcal Vaccines Market Overview
 7.3 Private
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Private: Geographic Segmentation Analysis
 7.4 Public
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Public : Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Meningococcal Vaccines Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 PFIZER INC
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 SANOFI
 8.4 SERUM INSTITUTE OF INDIA LTD
 8.5 GSK PLC
 8.6 MERCK & CO INC
 8.7 WALVAX BIOTECHNOLOGY CO LTD
 8.8 OTHER KEY PLAYERS

Chapter 9: Global Meningococcal Vaccines Market By Region
 9.1 Overview
 9.2. North America Meningococcal Vaccines Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Type
  9.2.4.1 Bivalent
  9.2.4.2 Quadrivalent
  9.2.4.3 Others
  9.2.5 Historic and Forecasted Market Size By Brand
  9.2.5.1 Menactra
  9.2.5.2 Menveo
  9.2.5.3 Nimenrix
  9.2.5.4 Trumenba
  9.2.5.5 Bexsero
  9.2.5.6 Others
  9.2.6 Historic and Forecasted Market Size By Serotype
  9.2.6.1 Serotype A
  9.2.6.2 Serotype B
  9.2.6.3 Serotype C
  9.2.6.4 Serotype W-135
  9.2.6.5 Serotype Y
  9.2.7 Historic and Forecasted Market Size By Sales Channel
  9.2.7.1 Private
  9.2.7.2 Public
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe Meningococcal Vaccines Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Type
  9.3.4.1 Bivalent
  9.3.4.2 Quadrivalent
  9.3.4.3 Others
  9.3.5 Historic and Forecasted Market Size By Brand
  9.3.5.1 Menactra
  9.3.5.2 Menveo
  9.3.5.3 Nimenrix
  9.3.5.4 Trumenba
  9.3.5.5 Bexsero
  9.3.5.6 Others
  9.3.6 Historic and Forecasted Market Size By Serotype
  9.3.6.1 Serotype A
  9.3.6.2 Serotype B
  9.3.6.3 Serotype C
  9.3.6.4 Serotype W-135
  9.3.6.5 Serotype Y
  9.3.7 Historic and Forecasted Market Size By Sales Channel
  9.3.7.1 Private
  9.3.7.2 Public
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Meningococcal Vaccines Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Type
  9.4.4.1 Bivalent
  9.4.4.2 Quadrivalent
  9.4.4.3 Others
  9.4.5 Historic and Forecasted Market Size By Brand
  9.4.5.1 Menactra
  9.4.5.2 Menveo
  9.4.5.3 Nimenrix
  9.4.5.4 Trumenba
  9.4.5.5 Bexsero
  9.4.5.6 Others
  9.4.6 Historic and Forecasted Market Size By Serotype
  9.4.6.1 Serotype A
  9.4.6.2 Serotype B
  9.4.6.3 Serotype C
  9.4.6.4 Serotype W-135
  9.4.6.5 Serotype Y
  9.4.7 Historic and Forecasted Market Size By Sales Channel
  9.4.7.1 Private
  9.4.7.2 Public
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Meningococcal Vaccines Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Type
  9.5.4.1 Bivalent
  9.5.4.2 Quadrivalent
  9.5.4.3 Others
  9.5.5 Historic and Forecasted Market Size By Brand
  9.5.5.1 Menactra
  9.5.5.2 Menveo
  9.5.5.3 Nimenrix
  9.5.5.4 Trumenba
  9.5.5.5 Bexsero
  9.5.5.6 Others
  9.5.6 Historic and Forecasted Market Size By Serotype
  9.5.6.1 Serotype A
  9.5.6.2 Serotype B
  9.5.6.3 Serotype C
  9.5.6.4 Serotype W-135
  9.5.6.5 Serotype Y
  9.5.7 Historic and Forecasted Market Size By Sales Channel
  9.5.7.1 Private
  9.5.7.2 Public
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Meningococcal Vaccines Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Type
  9.6.4.1 Bivalent
  9.6.4.2 Quadrivalent
  9.6.4.3 Others
  9.6.5 Historic and Forecasted Market Size By Brand
  9.6.5.1 Menactra
  9.6.5.2 Menveo
  9.6.5.3 Nimenrix
  9.6.5.4 Trumenba
  9.6.5.5 Bexsero
  9.6.5.6 Others
  9.6.6 Historic and Forecasted Market Size By Serotype
  9.6.6.1 Serotype A
  9.6.6.2 Serotype B
  9.6.6.3 Serotype C
  9.6.6.4 Serotype W-135
  9.6.6.5 Serotype Y
  9.6.7 Historic and Forecasted Market Size By Sales Channel
  9.6.7.1 Private
  9.6.7.2 Public
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America Meningococcal Vaccines Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Type
  9.7.4.1 Bivalent
  9.7.4.2 Quadrivalent
  9.7.4.3 Others
  9.7.5 Historic and Forecasted Market Size By Brand
  9.7.5.1 Menactra
  9.7.5.2 Menveo
  9.7.5.3 Nimenrix
  9.7.5.4 Trumenba
  9.7.5.5 Bexsero
  9.7.5.6 Others
  9.7.6 Historic and Forecasted Market Size By Serotype
  9.7.6.1 Serotype A
  9.7.6.2 Serotype B
  9.7.6.3 Serotype C
  9.7.6.4 Serotype W-135
  9.7.6.5 Serotype Y
  9.7.7 Historic and Forecasted Market Size By Sales Channel
  9.7.7.1 Private
  9.7.7.2 Public
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research